Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia - A Randomized Controlled Study.

A clinical trial, NCT06107335, is currently underway in the United States to compare the effects of albumin versus routine care on hemodynamic response and stability in pre-eclamptic patients during cesarean delivery. The study aims to determine if volume replacement with albumin, guided by stroke volume variation (SVV) using a ClearSight-Acumen monitor, improves hemodynamic stability in preeclamptic patients with severe features compared to routine care, under neuraxial anesthesia. The trial is in the interventional phase and is expected to be completed by May 2024. The study will compare the use of colloid and crystalloid fluids, with the experimental group receiving colloid fluid replacement and the control group receiving crystalloid fluid restriction. The eligibility criteria include gestational age greater than or equal to 24 weeks, a diagnosis of preeclampsia with severe features, and the need for neuraxial anesthesia. The study is not yet recruiting and is expected to be completed by November 2024. [Extracted from the article]